Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 55 and 90 years old at the time of signing the consent form
- People who have been diagnosed with Mild Cognitive Impairment or mild Alzheimer's disease-related dementia
- People who have been receiving an FDA-approved Alzheimer's antibody treatment — either Lecanemab (Leqembi) or Donanemab (Kisunla) — for at least 6 months before the infusion visit
- People who score between 20 and 26 on a standard memory and thinking test called the MMSE
- People who are able to give their own informed consent to participate
- People who have a family member or close friend (called a "study partner") who has regular, meaningful contact with them and can answer questions about their daily activities as part of the study
Who may not be able to join:
- People whose dementia is caused by something other than Alzheimer's disease
- People with severe, uncontrolled depression (those with depression that is well-managed may still be considered)
- People who are unable to independently give informed consent to participate
- People with a recent history of substance abuse
- People with a history of bleeding disorders, HIV, Hepatitis C (HCV), or Hepatitis B (HBV)
- People who have had cancer in the last 3 years, with some exceptions for certain treated skin cancers or early-stage cancers (confirm with trial site)
- People with uncontrolled high blood pressure, uncontrolled diabetes, unstable chest pain (angina), or a heart attack within the past year
- People who are currently taking, or have taken within the past four weeks, any experimental Alzheimer's treatment, or who have participated in another clinical trial within the past 3 months
- People who have received an organ transplant, or who have another active medical condition that the trial doctor believes could affect safety or the ability to complete the study
- People who are premenopausal (have not yet gone through menopause)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bernard S. Baumel, MD, University of Miami
Phone: (305) 243-3100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Alzheimer's Disease Scale-Cognitive Subscale (ADAS-Cog)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.